Condition Directory

Duchenne Muscular Dystrophy clinical trials

Directory of U.S. ClinicalTrials.gov public records for Duchenne Muscular Dystrophy. Browse Duchenne Muscular Dystrophy recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 24, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

237

Shown on this page

Current sort

How Duchenne Muscular Dystrophy studies are organized in the registry

Duchenne records are often titled with just “Duchenne” or the abbreviation DMD, and much of the portfolio is organized around a therapeutic platform — gene transfer, exon skipping — which appears in titles. Because Duchenne is diagnosed in childhood, the age filter meaningfully changes what you see.

Terms that often appear in related listings

DMD exon skipping gene therapy ambulatory

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 97–108 of 237 matching trials for Duchenne Muscular Dystrophy.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Muscular Dystrophy, Duchenne
Interventions: SRP-5051; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 7
States / cities: Hartford, Connecticut • Gulf Breeze, Florida • Atlanta, Georgia + 4 more

Conditions: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Interventions: Genetic characterization; Genetic
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Duchenne Muscular Dystrophy
Interventions: Pamrevlumab; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Pamrevlumab, Placebo, Corticosteroids; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 6 Years to 11 Years · Male only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 27
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 24 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Viltolarsen; Drug
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: 8 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Duchenne Muscular Dystrophy
Interventions: Allogeneic Cardiosphere-Derived Cells (CAP-1002); Biological
Lead sponsor: Capricor Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Gainesville, Florida • Cincinnati, Ohio

Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 17,667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Nonsene Mutation Duchenne Muscular Dystrophy
Interventions: Ataluren; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 6 Months to 2 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Duchenne Muscular Dystrophy
Interventions: Pamrevlumab, Placebo, Corticosteroids; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 24
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 21 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Years to 21 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Duchenne Muscular Dystrophy
Interventions: Amondys 45, Exondys 51, Vyondys 53; Drug
Lead sponsor: Kevin Flanigan; Other
Eligibility: 6 Months and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Muscular Dystrophy, Duchenne
Interventions: Spironolactone, Prednisolone; Drug
Lead sponsor: Kevin Flanigan; Other
Eligibility: 4 Years to 7 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Iowa City, Iowa • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more

About this Duchenne Muscular Dystrophy clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Duchenne Muscular Dystrophy as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Duchenne Muscular Dystrophy.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Duchenne Muscular Dystrophy clinical trials

How Duchenne Muscular Dystrophy studies are organized in the registry

Filter and sort this condition

Live official records

An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)

Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD

Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)

Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

Peak Cough Flow and Cough Clearance in Patients With Muscular Dystrophy

A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.

Spironolactone Versus Prednisolone in DMD

About this Duchenne Muscular Dystrophy clinical trials directory page